Volume 8, Issue 1 (1-2020)                   JoMMID 2020, 8(1): 7-13 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hamoon Navard S, Rezvan H, Feiz Haddad M H, Baghaban Eslaminejad M, Azami S. Expression of Cytokine Genes in Leishmania major-Infected BALB/c Mice Treated with Mesenchymal Stem Cells. JoMMID. 2020; 8 (1) :7-13
URL: http://jommid.pasteur.ac.ir/article-1-230-en.html
Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran
Abstract:   (133 Views)
Introduction: Cutaneous leishmaniasis (CL) is an infectious disease with a high rate of prevalence worldwide. No effective vaccine is now available for CL, and the current chemotherapy ensues serious side effects. The potency of Mesenchymal stem cells (MSCs) in immunomodulatory and wound healing have shown promise for the treatment of CL. Methods: In the present study, BALB/c mice were infected with leishmania major promastigotes and then injected with 1×106 MSCs at the lesion sites. After 10, 20, and 30 days, the lesion size in MSC-treated mice was measured and compared with that of controls received only PBS. Also, expression of IFN-γ, TNF-α, IL-12, IL-4, and IL-10 cytokines were assayed in lesions, neutrophils, spleen, and liver of both test and control groups using RT-PCR. Result: The lesion size significantly reduced in MSC-treated mice by day 30. Soon after the treatment, the expression of IFN-γ, TNF-α, and IL-10 genes, but not IL-4 was observed in the spleen and liver of the MSC-treated mice. In neutrophils of this group, only the TNF-α gene was expressed. Conclusion: our study exhibited the useful role of MSCs in the treatment of CL, which can open a new window to Leishmania research.
Full-Text [PDF 648 kb]   (35 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2019/12/27 | Accepted: 2020/06/20 | Published: 2020/01/11

References
1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7: 581-596. [DOI:10.1016/S1473-3099(07)70209-8]
2. Oryan A, Shirian S, Tabandeh MR, Hatam GR, Randau G, Daneshbod Y. Genetic diversity of Leishmania major strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA. Infect Genet Evol. 2013; 19: 226-231. [DOI:10.1016/j.meegid.2013.07.021]
3. Shirian S, Oryan A, Hatam GR, Tabandeh MR, Daneshmand E, Hashemi Orimi M, et al. Correlation of Genetic Heterogeneity with Cytopathological and Epidemiological Findings of Leishmania major Isolated from Cutaneous Leishmaniasis in Southern Iran. Acta Cytol. 2016; 60: 97-106. [DOI:10.1159/000445865]
4. Rafizadeh S, Saraei M, Abai M, Mohebali M, Bakhshi H, Rassi Y. Relationship between interleukin 4 gene promoter polymorphisms and cutaneous Leishmaniasis cases in North Eastern Iran. Biosci Biotech Res Comm. 2016; 9: 415-420. [DOI:10.21786/bbrc/9.3/11]
5. Bamorovat M, Sharifi I, Mohammadi MA, Eybpoosh S, Nasibi S, Aflatoonian MR, et al. Leishmania tropica isolates from non-healed and healed patients in Iran: A molecular typing and phylogenetic analysis. Microb Pathog. 2018; 116: 124-129. [DOI:10.1016/j.micpath.2018.01.021]
6. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010; 8: 419-433. [DOI:10.1586/eri.10.19]
7. Cummings HE, Tuladhar R, Satoskar AR. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J Biomed Biotechnol. 2010; 2010: 294389, 6. [DOI:10.1155/2010/294389]
8. Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, et al. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol. 2009; 70: 383-390. [DOI:10.1016/j.humimm.2009.01.007]
9. Guler ML, Gorham JD, Hsieh CS, Mackey AJ, Steen RG, Dietrich WF, et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science. 1996; 271: 984-987. [DOI:10.1126/science.271.5251.984]
10. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2: 845-858. [DOI:10.1038/nri933]
11. Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol. 2009; 47: 412-423.
12. Liew FY, Wei XQ, Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci. 1997; 352: 1311-1315. [DOI:10.1098/rstb.1997.0115]
13. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, Weber V, et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J. 2005; 19: 1000-1002. [DOI:10.1096/fj.04-3416fje]
14. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med. 2001; 194: 1497-1506. [DOI:10.1084/jem.194.10.1497]
15. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine. 2009; 27: 7036-7045. [DOI:10.1016/j.vaccine.2009.09.066]
16. Rezvan H, Moafi M. An overview on Leishmania vaccines: A narrative review article. Vet Res Forum. 2015; 6: 1-7.
17. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. Transl Res. 2013; 162: 144-155. [DOI:10.1016/j.trsl.2013.03.006]
18. Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JA. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. Cryobiology. 2015; 71: 181-197. [DOI:10.1016/j.cryobiol.2015.07.003]
19. Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med. 2012; 1: 51-58. [DOI:10.5966/sctm.2011-0019]
20. Doorn J, Moll G, Le Blanc K, van Blitterswijk C, de Boer J. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 2012; 18: 101-115. [DOI:10.1089/ten.teb.2011.0488]
21. Stoff A, Rivera AA, Sanjib Banerjee N, Moore ST, Michael Numnum T, Espinosa-de-Los-Monteros A, et al. Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol. 2009; 18: 362-369. [DOI:10.1111/j.1600-0625.2008.00792.x]
22. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008; 5: 453-463. [DOI:10.1111/j.1742-481X.2007.00408.x]
23. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet. 2011; 20: 790-805. [DOI:10.1093/hmg/ddq523]
24. Pereira JC, Ramos TD, Silva JD, de Mello MF, Pratti JES, da Fonseca-Martins AM, et al. Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced by Leishmania amazonensis. Front Immunol. 2017; 8: 893. [DOI:10.3389/fimmu.2017.00893]
25. Dameshghi S, Zavaran-Hosseini A, Soudi S, Shirazi FJ, Nojehdehi S, Hashemi SM. Mesenchymal stem cells alter macrophage immune responses to Leishmania major infection in both susceptible and resistance mice. Immunol Lett. 2016; 170: 15-26. [DOI:10.1016/j.imlet.2015.12.002]
26. Khosrowpour Z, Hashemi SM, Mohammadi-Yeganeh S, Soudi S. Pretreatment of Mesenchymal Stem Cells With Leishmania major Soluble Antigens Induce Anti-Inflammatory Properties in Mouse Peritoneal Macrophages. J Cell Biochem. 2017; 118: 2764-2779. [DOI:10.1002/jcb.25926]
27. Rezapour A, Majidi J. An improved method of neutrophil isolation in peripheral blood of sheep. J Anim Vet Adv. 2009; 8: 11-15.
28. Baghban Eslaminezhad M, Nazarian H, Taghiyar L. Mesenchymal stem cells with high growth rate in the supernatant medium from rat bone marrow primary culture. 2008.
29. Hay C WO. Practical immunology. 4th edBlackwell Science Ltd Berlin, Germany, 2002: 203-210. [DOI:10.1002/9780470757475]
30. Laurenti MD, Gidlund M, Ura DM, Sinhorini IL, Corbett CE, Goto H. The role of natural killer cells in the early period of infection in murine cutaneous leishmaniasis. Braz J Med Biol Res. 1999; 32: 323-325. [DOI:10.1590/S0100-879X1999000300012]
31. Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol. 2003; 131: 457-467. [DOI:10.1046/j.1365-2249.2003.02096.x]
32. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med. 1999; 189: 741-746. [DOI:10.1084/jem.189.4.741]
33. Wu W, Huang L, Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur J Immunol. 2010; 40: 2517-2527. [DOI:10.1002/eji.201040484]
34. Anderson CF, Mendez S, Sacks DL. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol. 2005; 174: 2934-2941. [DOI:10.4049/jimmunol.174.5.2934]
35. Du L, Lv R, Yang X, Cheng S, Ma T, Xu J. Hypoxic conditioned medium of placenta-derived mesenchymal stem cells protects against scar formation. Life Sci. 2016; 149: 51-57. [DOI:10.1016/j.lfs.2016.02.050]
36. Rodrigues C, de Assis AM, Moura DJ, Halmenschlager G, Saffi J, Xavier LL, et al. New therapy of skin repair combining adipose-derived mesenchymal stem cells with sodium carboxymethylcellulose scaffold in a pre-clinical rat model. PLoS One. 2014; 9: e96241. [DOI:10.1371/journal.pone.0096241]
37. Hamounnavard S, Delirezh N. The effect of Rat mesenchymal stem cells and its soluble factors on peripheral blood neutrophil function. Armaghan-e-Danesh. 2013; 19: 1341-1349.
38. Abreu SC, Antunes MA, Xisto DG, Cruz FF, Branco VC, Bandeira E, et al. Bone Marrow, Adipose, and Lung Tissue-Derived Murine Mesenchymal Stromal Cells Release Different Mediators and Differentially Affect Airway and Lung Parenchyma in Experimental Asthma. Stem Cells Transl Med. 2017; 6: 1557-1567. [DOI:10.1002/sctm.16-0398]
39. Akhzari S, Rezvan H, Zolhavarieh M. Expression of Pro-inflammatory Genes in Lesions and Neutrophils during Leishmania major Infection in BALB/c Mice. Iran J Parasitol. 2016; 11: 534-541.
40. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96: 41-101. [DOI:10.1016/S0065-2776(07)96002-2]
41. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol. 1990; 145: 4306-4310.
42. Guijarro D, Lebrin M, Lairez O, Bourin P, Piriou N, Pozzo J, et al. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial. Int J Cardiol. 2016; 209: 258-265. [DOI:10.1016/j.ijcard.2016.02.016]
43. Nacy CA, Meltzer MS, Leonard EJ, Wyler DJ. Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. J Immunol. 1981; 127: 2381-2386.
44. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. 2005; 101: 226-230. [DOI:10.1016/j.imlet.2005.06.004]
45. Wang ZY, Sato H, Kusam S, Sehra S, Toney LM, Dent AL. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J Immunol. 2005; 174: 2098-2105. [DOI:10.4049/jimmunol.174.4.2098]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.